Pulmonary administration of functionalized nanoparticles significantly reduces beta-amyloid in the brain of an Alzheimer’s disease murine model
| Autor: | Francesca Re, Marco Gobbi, Giulio Sancini, Gianluigi Forloni, Roberta Dal Magro, Mario Salmona, F Ornaghi, Claudia Balducci |
|---|---|
| Přispěvatelé: | Sancini, G, DAL MAGRO, R, Ornaghi, F, Balducci, C, Forloni, G, Gobbi, M, Salmona, M, Re, F |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Amyloid Peptide Nanotechnology 02 engineering and technology Pharmacology 03 medical and health sciences chemistry.chemical_compound BIO/09 - FISIOLOGIA In vivo ApoE-derived peptide lung administration nanoparticles Alzheimer’s disease liposomes Medicine General Materials Science Electrical and Electronic Engineering Beta (finance) ApoE-derived peptide chemistry.chemical_classification Liposome Lung business.industry nanoparticle Phosphatidic acid 021001 nanoscience & nanotechnology Condensed Matter Physics Atomic and Molecular Physics and Optics In vitro 030104 developmental biology medicine.anatomical_structure lung administration chemistry liposome 0210 nano-technology business Alzheimer’s disease |
| Zdroj: | Nano Research. 9:2190-2201 |
| ISSN: | 1998-0000 1998-0124 |
| DOI: | 10.1007/s12274-016-1108-8 |
| Popis: | Treatment options for Alzheimer’s disease (AD) are limited because of the inability of drugs to cross the blood–brain barrier (BBB). A promising strategy to overcome this obstacle is the use of nanoparticles (NPs). Previously, we showed that intraperitoneal administration of liposomes functionalized with phosphatidic acid and an ApoE-derived peptide (mApoE-PA-LIP) reduces brain beta-amyloid (Aβ) burden and ameliorates impaired memory in AD mice. Here, we investigated lung administration as an alternative, non-invasive NP delivery route for reaching the brain. Our results show that mApoE-PA-LIP were able to cross the pulmonary epithelium ([14C]-PA permeability = 6.5 ± 2.0 × 10–6 cm/min) in vitro and reach the brain (up to 0.6 μg PA/g brain) following in vivo intratracheal instillations. Lung administration of mApoE-PA-LIP to AD mice significantly decreased total brain Aβ (–60%; p < 0.05) compared to untreated mice. These results suggest that pulmonary administration could be exploited for brain delivery of NPs designed for AD therapy. [Figure not available: see fulltext.] |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink